Diagnosis

Polycystic ovary syndrome

A variable disorder that is marked by amenorrhea, hirsutism, obesity and infertility in association with cystic ovarian enlargement.

Etiology

Cause [eht]

Pathofysiology [eht]

  1. Elevated LH -> ovarian theca cells increase production of androgens -> elevated LH/FSH-ratio -> failure to aromatize the androgens to estrogens -> decreased estrogen levels and anovulation -> arrest in maturation -> ovarian cysts

  2. Insulin resistance --> hyperinsulinemia

  3. Dysfunction of the hypothalamic-pituitary-ovarian axis

    • Increased Antimullerian hormone and Luteinizing hormone (LH)

    • Ovarian steroidogenesis --> androgen excess

  4. Increased risk for:

    • Infertility

    • Metabolic syndrome

    • Obesity

    • Diabetes type 2

    • Cardiovascular risk

    • Depression

    • Obstructive sleep apnea

    • Endometrial cancer

    • Metabolic dysfunction-associated steatotic liver disease (MASLD)

Risk factors [eht]

Complications [eht]

Epidemiology

Incidence per 100.000 [qnw][osw][oh6][ipi]

Epidemiology chart for Incidence

Prevalence per 100.000 [qnw][osw][oh6][ipi]

Epidemiology chart for Prevalence

Approach

Rotterdam diagnostic criteria - presence of 2 of the following [ixu]

Treatment

  1. Lifestyle modifications: [ixu]

    • Weight loss

    • Increased exercise

    • Change in diet

  2. Menstrual abnormalities and hirsutism/acne --> hormonal contraceptives [ixu]

  3. Metabolic/glycemic abnormalities --> Metformin and GLP-1 agonists [eht]

  4. Infertility --> Clomiphene

  5. Adrenal hyperandrogenism --> Prednisone, dexamethasone, spironolactone

  6. Treat cardiovascular risk, diabetes, endometrial cancer, mood disorders, and obstructive sleep apnea

  7. Bariatric surgery [eht]

Differential diagnoses

Acromegaly, Adrenal cortical adenoma, Adrenal cortical carcinoma, Anabolic steroids, Congenital adrenal hyperplasia, Cushings disease, Cushing syndrome, Diabetes mellitus, Drug side effects, Early menopause, Eating disorder, Familial hirsutism, Gigantism, Hyperprolactinemia, Hyperthyroidism, Hypothyroidism, Idiopathic hirsutism, Obesity, Ovarian cancer, Ovarian hyperthecosis, Pituitary adenoma


References

[1] Shukla A, Rasquin LI, Anastasopoulou C. Polycystic Ovarian Syndrome. [Updated 2025 Jul 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459251/

[2] Jiang B. The Global Burden of Polycystic Ovary Syndrome in Women of Reproductive Age: Findings from the GBD 2019 Study. Int J Womens Health. 2025 Jan 25;17:153-165.

[3] Gao Y, Liu H, Qiao L, Liang J, Yao H, Lin X, Gao Y. Study of Burden in Polycystic Ovary Syndrome at Global, Regional, and National Levels from 1990 to 2019. Healthcare (Basel). 2023 Feb 14;11(4):562.

[4] Lin L, Li, W, Xu B, Li Y, Li J, Kong X, Du X. Global Trends in Polycystic Ovarian Syndrome Over 30 Years: An Age-Period-Cohort Study of 204 Countries and Territories (1990- 2021).

[5] Yu O, Christ JP, Schulze-Rath R, Covey J, Kelley A, Grafton J, Cronkite D, Holden E, Hilpert J, Sacher F, Micks E, Reed SD. Incidence, prevalence, and trends in polycystic ovary syndrome diagnosis: a United States population-based study from 2006 to 2019. Am J Obstet Gynecol. 2023 Jul;229(1):39.e1-39.e12.

[6] http://emedicine.medscape.com/article/256806 (2014-01-02); [Medscape]

[7] Huo, M., Wang, Y., Yuan, X. et al. Changing trends in the global burden of polycystic ovarian syndrome-related infertility over the past 30 years: retrospective data analysis of the global burden of disease study 2019. BMC Women's Health 25, 35 (2025).

Scroll to top